Anti-SPRY3 monoclonal antibody

Pre-made anti-SPRY3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SPRY3/SPRY3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1814-Ab-1/ GM-Tg-hg-IP1814-Ab-2Anti-Human SPRY3 monoclonal antibodyHuman
GM-Tg-rg-IP1814-Ab-1/ GM-Tg-rg-IP1814-Ab-2Anti-Rat SPRY3 monoclonal antibodyRat
GM-Tg-mg-IP1814-Ab-1/ GM-Tg-mg-IP1814-Ab-2Anti-Mouse SPRY3 monoclonal antibodyMouse
GM-Tg-cynog-IP1814-Ab-1/ GM-Tg-cynog-IP1814-Ab-2Anti-Cynomolgus/ Rhesus macaque SPRY3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1814-Ab-1/ GM-Tg-felg-IP1814-Ab-2Anti-Feline SPRY3 monoclonal antibodyFeline
GM-Tg-cang-IP1814-Ab-1/ GM-Tg-cang-IP1814-Ab-2Anti-Canine SPRY3 monoclonal antibodyCanine
GM-Tg-bovg-IP1814-Ab-1/ GM-Tg-bovg-IP1814-Ab-2Anti-Bovine SPRY3 monoclonal antibodyBovine
GM-Tg-equg-IP1814-Ab-1/ GM-Tg-equg-IP1814-Ab-2Anti-Equine SPRY3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1814-Ab-1/ GM-Tg-hg-IP1814-Ab-2; GM-Tg-rg-IP1814-Ab-1/ GM-Tg-rg-IP1814-Ab-2;
GM-Tg-mg-IP1814-Ab-1/ GM-Tg-mg-IP1814-Ab-2; GM-Tg-cynog-IP1814-Ab-1/ GM-Tg-cynog-IP1814-Ab-2;
GM-Tg-felg-IP1814-Ab-1/ GM-Tg-felg-IP1814-Ab-2; GM-Tg-cang-IP1814-Ab-1/ GM-Tg-cang-IP1814-Ab-2;
GM-Tg-bovg-IP1814-Ab-1/ GM-Tg-bovg-IP1814-Ab-2; GM-Tg-equg-IP1814-Ab-1/ GM-Tg-equg-IP1814-Ab-2
Products NameAnti-SPRY3 monoclonal antibody
Formatmab
Target NameSPRY3
Protein Sub-locationIntrocelluar Protein
Category of antibodyCytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SPRY3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1814-Ag-1Recombinant multi-species SPY3/ SPRY3/ spry-3 protein
    CytokineGM-Tg-g-IP1814-Ag-1sprouty homolog 3 (Drosophila) (SPRY3) protein


    Target information

    Target IDGM-IP1814
    Target NameSPRY3
    Gene ID10251,236576,498159,703923,492271,101094659,539402,100062480
    Gene Symbol and SynonymsGm1409,Gm391,RGD1562172,sprouty3,spry-3,SPRY3
    Uniprot AccessionO43610
    Uniprot Entry NameSPY3_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryCytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000168939
    Target ClassificationN/A

    The target: SPRY3, gene name: SPRY3, also named as spry-3. Involved in negative regulation of MAPK cascade. Predicted to be located in membrane. Predicted to be active in cytosol. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.